Loading
Life sciences · Journal article
Frontiers. · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Human papillomavirus (HPV) is the primary etiological agent of cervical cancer, a disease that remains a major cause of cancer-related morbidity and mortality among women in Kenya despite the availability of highly effective prophylactic vaccines. This review examines the current evidence on HPV virology, vaccine immunology, global vaccine effectiveness, and the implementation of HPV vaccination in Kenya following its introduction into the national immunization program in 2019. It also evaluates progress in vaccine delivery, coverage trends, and the adoption of the single-dose vaccination schedule, while highlighting persistent challenges including vaccine hesitancy, inequitable access, health system constraints, and socioeconomic barriers. Available evidence indicates that HPV vaccination has strengthened cervical cancer prevention efforts and has the potential to substantially reduce the future burden of HPV-related disease. However, vaccine coverage remains below the World Health Organization target for cervical cancer elimination, limiting the full public health impact of the program. Key research priorities include evaluating long-term vaccine effectiveness, monitoring HPV genotype dynamics, assessing vaccine performance among people living with HIV, and strengthening the integration of HPV vaccination with cervical cancer screening programs. Achieving equitable vaccine access, enhancing surveillance systems, improving community engagement, and ensuring sustainable financing will be essential to maximizing the benefits of HPV vaccination and accelerating progress toward the elimination of cervical cancer in Kenya.